CELL INTELLIGENCE · 肿瘤细胞治疗研究

多发性骨髓瘤中 CAR-T、双特异性抗体与抗体偶联药物的毒性：风险减轻与管理的实用方法

Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management.

利用 CAR-NK 细胞对抗多发性骨髓瘤：当前格局与未来方向

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

CAR-NK 疗法正从一种有前景的概念演变为针对 MM 的现实治疗平台。

多发性骨髓瘤的治疗前沿：临床试验新兴格局分析

Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials.

多发性骨髓瘤临床试验的增加凸显了向生物治疗的转变，尤其是免疫治疗和 CAR-T 等基因治疗。

多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述

State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.

多发性骨髓瘤 CAR 治疗的靶点

Targets for CAR Therapy in Multiple Myeloma.

靶向 GPRC5D 的 CAR-T 细胞疗法治疗多发性骨髓瘤患者的安全性和有效性的系统评价和荟萃分析：癌症免疫治疗的新见解

A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insig

GPRC5D 是一个活跃且安全的靶点，在治疗复发和/或难治性（R/R）MM 及经过大量预处理的患者中显示出有希望的结果。

双特异性抗体治疗多发性骨髓瘤

Bispecific antibodies in the treatment of multiple myeloma.